Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04793958 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
A Phase 3 study of Metastatic Colorectal Cancer and Advanced Colorectal Cancer, sponsored by Mirati Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 461
- Enrollment target
- 20
- Study locations
NCT04793958 is a Phase 3 study of Metastatic Colorectal Cancer and Advanced Colorectal Cancer that is active but no longer recruiting, run by Mirati Therapeutics. The registered enrollment target is 461 participants, above the 176-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (162% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT04793958, a Phase 3 study of Metastatic Colorectal Cancer and Advanced Colorectal Cancer, is active but no longer recruiting, sponsored by Mirati Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 461 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.
Conditions Studied
Interventions
- BIOLOGICAL Cetuximab
- DRUG FOLFIRI Regimen
- DRUG MRTX849
- DRUG mFOLFOX6 Regimen
Study Locations (20)
California
- Local Institution - 010-573 - Bakersfield
- Local Institution - 010-979C - Chula Vista
- Local Institution - 010-980 - Fresno
- Local Institution - 010-851 - Fullerton
- Local Institution - 010-979A - La Mesa
- Local Institution - 010-958A - Los Angeles
- Local Institution - 010-958 - Los Angeles
- Local Institution - 010-551 - Los Angeles
- Local Institution - 010-847 - Newport Beach
Alabama
- Local Institution - 010-855-E - Alabaster
- Local Institution - 010-855-B - Bessemer
- Local Institution - 010-855-D - Birmingham
- Local Institution - 010-855-A - Birmingham
- Local Institution - 010-855-F - Birmingham
- Local Institution - 010-855-C - Birmingham
- Local Institution - 010-855 - Birmingham
Arizona
- Local Institution - 010-996 - Gilbert
- Local Institution - 010-566 - Goodyear
- Local Institution - 010-989 - Phoenix
Arkansas
- Local Institution - 010-978 - Springdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 461 participants |
| Start Date | 2021-06-24 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04793958
The ClinicalTrials.gov registry entry for NCT04793958 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 461 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 176-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (162% higher). The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Cetuximab is the first listed.
NCT04793958 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT04793958 about?
NCT04793958 is a clinical study titled "Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)". Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.
What is the current status of trial NCT04793958?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 461 participants. The study started on 2021-06-24. Estimated completion is 2026-01-30.
What conditions does trial NCT04793958 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer, Advanced Colorectal Cancer.
What interventions are being tested in trial NCT04793958?
The interventions under investigation include: Cetuximab (BIOLOGICAL), FOLFIRI Regimen (DRUG), MRTX849 (DRUG), mFOLFOX6 Regimen (DRUG).
Who is sponsoring clinical trial NCT04793958?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04793958 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
RECRUITING · Phase 3
-
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
RECRUITING · Phase 3
-
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
ACTIVE NOT RECRUITING · Phase 3
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 1
-
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.